TY - JOUR
T1 - Diagnosis and management of acute myeloid leukemia in children and adolescents
T2 - Recommendations from an international expert panel
AU - Creutzig, Ursula
AU - Van Den Heuvel-Eibrink, Marry M.
AU - Gibson, Brenda
AU - Dworzak, Michael N.
AU - Adachi, Souichi
AU - De Bont, Eveline
AU - Harbott, Jochen
AU - Hasle, Henrik
AU - Johnston, Donna
AU - Kinoshita, Akitoshi
AU - Lehrnbecher, Thomas
AU - Leverger, Guy
AU - Mejstrikova, Ester
AU - Meshinchi, Soheil
AU - Pession, Andrea
AU - Raimondi, Susana C.
AU - Sung, Lillian
AU - Stary, Jan
AU - Zwaan, Christian M.
AU - Kaspers, Gertjan J.L.
AU - Reinhardt, Dirk
PY - 2012
Y1 - 2012
N2 - Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML) remains a life-threatening malignancy in children, with current survival rates of ∼ 70%. State-of-the-art recommendations in adult AML have recently been published in this journal by Döhner et al. The primary goal of an international expert panel of the International BFM Study Group AML Committee was to set standards for the management, diagnosis, response assessment, and treatment in childhood AML. This paper aims to discuss differences between childhood and adult AML, and to highlight recommendations that are specific to children. The particular relevance of new diagnostic and prognostic molecular markers in pediatric AML is presented. The general management of pediatric AML, the management of specific pediatric AML cohorts (such as infants) or subtypes of the disease occurring in children (such as Down syndrome related AML), as well as new therapeutic approaches, and the role of supportive care are discussed.
AB - Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML) remains a life-threatening malignancy in children, with current survival rates of ∼ 70%. State-of-the-art recommendations in adult AML have recently been published in this journal by Döhner et al. The primary goal of an international expert panel of the International BFM Study Group AML Committee was to set standards for the management, diagnosis, response assessment, and treatment in childhood AML. This paper aims to discuss differences between childhood and adult AML, and to highlight recommendations that are specific to children. The particular relevance of new diagnostic and prognostic molecular markers in pediatric AML is presented. The general management of pediatric AML, the management of specific pediatric AML cohorts (such as infants) or subtypes of the disease occurring in children (such as Down syndrome related AML), as well as new therapeutic approaches, and the role of supportive care are discussed.
UR - http://www.scopus.com/inward/record.url?scp=84868129082&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-03-362608
DO - 10.1182/blood-2012-03-362608
M3 - Review article
C2 - 22879540
AN - SCOPUS:84868129082
SN - 0006-4971
VL - 120
SP - 3167
EP - 3205
JO - Blood
JF - Blood
IS - 16
ER -